Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Gross Profit: 2019-2024

Historic Gross Profit for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $108.3 million.

  • Maravai Lifesciences Holdings' Gross Profit fell 82.46% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of $108.3 million for FY2024, which is 22.75% down from last year.
  • Maravai Lifesciences Holdings' Gross Profit amounted to $108.3 million in FY2024, which was down 22.75% from $140.2 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Gross Profit ranged from a high of $714.0 million in FY2022 and a low of $108.3 million during FY2024.
  • Moreover, its 3-year median value for Gross Profit was $140.2 million (2023), whereas its average is $320.9 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Gross Profit soared by 222.17% in 2021, and later tumbled by 80.37% in 2023.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Gross Profit stood at $204.4 million in 2020, then skyrocketed by 222.17% to $658.7 million in 2021, then rose by 8.41% to $714.0 million in 2022, then slumped by 80.37% to $140.2 million in 2023, then fell by 22.75% to $108.3 million in 2024.